Kirsty, Biocon's rapid-acting insulin, is the first FDA-approved interchangeable biosimilar to NovoLog in the US and will be ...

The US Food and Drug Administration approved, the first rapid-acting interchangeable biosimilar product, Kirsty (insulin ...

Kirsty is biosimiler to Novolog. It is a rapid-acting human insulin analog indicated to improve glycemic control in adults ...

The US diabetes market presents a substantial opportunity for Biocon Biologics, with 38.4 million people living with diabetes ...

BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, July 15, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd (BBL) , a fully int ...

Biocon share price today: Shares of Biocon witnessed a 3 per cent gain, logging an intraday high of ₹405.9 on Wednesday after ...

Biocon Biologics has secured USFDA approval for Kirsty. Kirsty is an interchangeable biosimilar to NovoLog, used for diabetes ...

The biosimilars market is estimated to reach USD 66.9 billion by 2028 from USD 29.4 billion in 2023, at a CAGR of 17.8% ...

Three insulin products are currently in shortage, ... Novo Nordisk is discontinuing Levemir and has a shortage of some Insulin Aspart and Novolog products. Other insulin injections are not in ...

Biocon Biologics Ltd today announced that the U.S. Food and Drug Administration has approved Kirsty™ (Insulin Aspart-xjhz), ...

Insulin Aspart is a rapid-acting type of insulin sold as generic Insulin Aspart and under the brand name Novolog, the ADCES says. Another version of Insulin Aspart, Fiasp, ...

Three insulin products are currently in shortage, but all other insulin products are in good supply, including alternatives for the limited products.